Alzheimer’s Biomarker Benefit From Failed Janssen BACE Inhibitor?
New access agreement for samples from failed clinical trial to support identification of valuable new biomarkers, and possibly novel drugs, in highly challenging disorder.
You may also be interested in...
Lundbeck executive calls for adaptive trial designs, transdiagnostic approach, and more scientific discussions between sponsors and the US Food and Drug Administration.
Biogen surprised investors with news that it will file aducanumab with the FDA based on data from more patients treated at the highest dose than in the interim futility analysis that led to termination of two Phase III studies in March.
Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.